Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$135.82-0.40%
Close 2026-07-08 · 1-day change
Reading GILD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GILD free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading GILD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GILD free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on consistent revenue growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to increasing product sales.
The market appears to have priced in a neutral valuation, reflecting a low expectations gap compared to peers. Gilead is seen as relatively cheap against its competitors, but there is a fragility due to weak execution quality.
Fundamentals are likely to show continued growth, particularly in product sales excluding Veklury, which have increased year-over-year. However, there is a moderate risk due to the potential for misses in upcoming earnings, especially given the recent history of industry peers.
The thesis hinges on Gilead's ability to raise guidance in the next quarter and the performance of sector bellwethers like LLY, JNJ, and ABBV. Positive momentum in the healthcare sector could bolster Gilead, while negative trends among peers could pose risks.
Overall, Gilead Sciences is positioned for steady growth, but external factors and execution quality will be crucial in shaping its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Additionally, FDA approval for Trodelvy is expected to increase product sales. There are no current threats to this improved view.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will provide insights on revenue trends and management's outlook for the rest of the year.
Confirms one read:Q2 earnings report shows revenue growth exceeding 5% year over year.
Confirms the other:Q2 earnings report shows revenue growth below 2% year over year.
Why it matters: Earnings that meet or exceed raised guidance would confirm Gilead's growth trajectory. Missed targets could raise concerns about future performance.
Confirms:Q2 2026 earnings report shows results in line with or above the raised guidance.
Disproves:Q2 2026 earnings report falls short of the raised guidance.
Why it matters: The FDA's decision on BIC/LEN affects Gilead's HIV portfolio. A positive decision could boost sales.
Confirms:FDA approves BIC/LEN for people with HIV who have low virus levels.
Disproves:FDA rejects or delays the decision on BIC/LEN.
Why it matters: The FDA's choice on anito-cel is key for Gilead's cancer plans and future money.
Confirms:FDA approves anito-cel for multiple myeloma that has come back or is hard to treat.
Disproves:FDA does not approve or delays the choice on anito-cel.
Why it matters: Hitting sales goals for anito-cel could lead to extra payments. It would also support the acquisition.
Confirms:Gilead says total global net sales of anito-cel hit $6 billion.
Disproves:Gilead says total global net sales of anito-cel are still under $6 billion.
Why it matters: Continued growth in product sales shows strong demand and market position. This supports Gilead's revenue outlook.
Confirms:Product sales excluding Veklury increase more than 8% YoY in Q2 2026.
Disproves:Product sales excluding Veklury increase less than 5% YoY in Q2 2026.